NASDAQ:HUMA
Humacyte, Inc.
Humacyte, Inc.'s revenue was $2.0M in fiscal 2025. Free cash flow was −$105.9M, −5197.5% of revenue, and the diluted share count rose 33.5%.Summary generated from Humacyte, Inc.'s SEC filings. Latest annual report filed Mar 27, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$2.0M
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross margin−376.1%
Operating margin−5306.0%
Net margin−2003.6%
ROICn/a
Return on equityn/a
Debt / equity11.40
Free cash flow−$105.9M
FCF margin−5197.5%
Share count change+33.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | 0 | 2 |
| Operating income | −81 | −85 | −100 | −114 | −108 |
| Net income | −26 | −12 | −111 | −149 | −41 |
| Free cash flow | −81 | −72 | −76 | −100 | −106 |
Recent filings
- 4Insider transaction report
Oct 7, 2026 - 4Insider transaction report
Oct 7, 2026 - 8-KDirector or officer change
Sep 28, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KResults of operations and financial condition
Aug 12, 2026 - 8-KNotice of delisting or listing-rule failure
Jul 31, 2026 - 8-KEntry into a material agreement
Jun 11, 2026 - 8-KOther events
Jun 10, 2026